Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis AMERICAN JOURNAL OF HEMATOLOGY Sidana, S., Sidiqi, M., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Muchtar, E., Dingli, D., Haynnan, S. R., Gonsalves, W., Kapoor, P., Leung, N., Warsame, R., Kourelis, T., Wolf, R. C., Hogan, W. J., Kumar, S. K., Gertz, M. A. 2019

Abstract

In appropriately selected patients with AL amyloidosis, autologous stem cell transplant (ASCT) is an established treatment modality with excellent outcomes and decreasing transplant related mortality (TRM) over time. We report on 15-year overall survival (OS) in 159 patients undergoing ASCT from 1996 to 2003, with median follow up of 17.1 years. Day 100 TRM was 13.2% (n = 21). The OS of =15?years was observed in 30% (47/159) of patients. Patients surviving =15?years were younger (53 vs 56?years, P = .02), less likely to have lambda as the involved light chain (62% vs 78%, P = .03) and were less likely to have heart involvement (32% vs 56%, P = .005). Median OS of patients with heart involvement vs not was 4.0 vs 11.1 years, P = .006 and actuarial 15-year OS was 23% vs 43%, respectively. A higher proportion of patients with OS =15?years received full-dose melphalan conditioning (81% vs 61%, P = .01), and achieved day 100 complete response (CR) (64% vs 24%, P?

View details for DOI 10.1002/ajh.25566

View details for Web of Science ID 000474995300001

View details for PubMedID 31254301